US EditionLong-term survival rates of some acute myeloid leukemia patients could double with sensitive bone marrow test
- A clinical trial led by King’s College London from 2012 to 2018 in the UK demonstrated that a specialized molecular assay detecting minimal residual disease in bone marrow can potentially double survival rates for certain younger adults with acute myeloid leukemia.
- The test detects minimal residual disease earlier than routine methods, identifying relapse up to three months before symptoms, which allows timely treatment adjustments.
- The trial monitored 637 patients in remission, chiefly with NPM1 and FLT3 gene mutations, and showed that early molecular detection prevents emergency relapse interventions and maintains patient health.
- Professor Nigel Russell said about one third of patients doubled their survival, calling the result a 'massive improvement,' while Jane Leahy credited the trial with saving her life by enabling alternative treatment.
- The test is being integrated into NHS care across the UK, signaling a shift toward molecular surveillance as a standard in AML treatment and offering hope to improve outcomes for aggressive blood cancers.
11 Articles
11 Articles
Discovered a key mechanism that evolves chronic leukemia into Richter's syndrome
A fundamental mechanism has been identified in the transformation of chronic lymphatic leukaemia into a particularly aggressive and resistant lymphoma to conventional therapies called Richter's syndrome. The study was conducted by Professor Paolo Sportoletti and by the research group of researchers working for the Hematology section of the Department of Medicine and Surgery of the University of Perugia. The research benefited from the funding of…
Bone marrow tests ‘double survival time for blood cancer patients’, trial finds
The 10-minute procedure identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests. A highly sensitive test that detects traces of disease in the bone marrow of patients with a rare and aggressive type of blood cancer could help double their chances of survival, a first-of-its-kind trial has found. The 10-minute procedure – which involves an injection in the hip bone every three months – identified si…
Long-term survival rates of some acute myeloid leukemia patients could double with sensitive bone marrow test
A highly sensitive bone marrow test could double survival rates for some groups of younger adults with acute myeloid leukemia (AML) by helping doctors identify if they might relapse up to three months earlier.
Acute Myeloid Leukemia Subgroup Survival Rates Improve by 50% with MRD Monitoring
A new patient-specific bone marrow testing protocol that detects minimal residual disease (MRD) in acute myeloid leukemia (AML) could significantly improve outcomes for certain high-risk patients, doubling survival rates for a subgroup of younger adults. According to the research, published in The Lancet Haematology, the study found that in patients with mutations in the NPM1 and FLT3-ITD genes, which are most common among younger adults with AM…
Bone marrow tests double survival time for blood cancer patients trial finds - Banbury FM
A highly sensitive test that detects traces of disease in the bone marrow of patients with a rare and aggressive type of blood cancer could help double their chances of survival, a first-of-its-kind trial has found. The 10-minute procedure – which involves an injection in the hip bone every three months – identified signs of acute myeloid leukaemia (AML) returning in patients before it showed in blood tests. This gives medics a “window of opport…
Coverage Details
Bias Distribution
- 75% of the sources lean Left
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
